Genfit May Be Gaining An Edge In NASH Race
With Intercept encountering safety concerns for Ocaliva and mixed data for Gilead's and Allergan's NASH candidates, Genfit may hold an advantage with NASH clearance ability and clean safety profile.
With Intercept encountering safety concerns for Ocaliva and mixed data for Gilead's and Allergan's NASH candidates, Genfit may hold an advantage with NASH clearance ability and clean safety profile.